Propofol is commonly used for the sedation of critically ill patients undergoing mechanical ventilation. These patients may develop tolerance during long-term administration. Here, we describe the development of tolerance to propofol's sedative effect in rabbits during prolonged mechanical ventilation. Six healthy male New Zealand White rabbits were endotracheally intubated and received propofol by continuous IV infusion to maintain sedation for 48 h. The propofol infusion rate (IR) was adjusted to maintain the desired level of sedation. Assessments of the sedation level were made every 30 min or earlier if there were signs of awakening. Propofol concentrations were measured in arterial plasma after every other IR adjustment, provided there was an adequate level of sedation, using high performance liquid chromatography, and calculations of systemic clearance rates were made. The mortality rate was 100% with a survival period of 30.8 Ϯ 6.0 h (mean Ϯ sd). The course of IR adjustments followed a 5-phase pattern: 1) steady IR (mean Ϯ sd duration; 1.2 Ϯ 0.6 h), 2) increasing IR (9.4 Ϯ 5.5 h), 3) steady high-IR (2.3 Ϯ 1.2 h), 4) decreasing IR (13.7 Ϯ 1.9 h), and 5) steady low-IR (5.0 Ϯ 2.7 h). The course of propofol concentrations during the experiment in relation to propofol IR followed a 3-phase pattern: 1) steady concentration with increasing IRs (6.0 Ϯ 2.7 h), 2) increasing concentrations with increasing IR (5.8 Ϯ 2.5 h), and 3) increasing concentrations with decreasing IR (18.8 Ϯ 3.3 h). Propofol systemic clearance rates were progressively increased for 6.0 Ϯ 2.7 h and then gradually decreased for 24.6 Ϯ 4.7 h. In conclusion, all rabbits developed tolerance to propofol's sedative effect within the first hours of administration related to changes to the drug's metabolic clearance.
Propof ol is an alkylphenol (2,6-diisopropylphenol) hypnotic drug used for the induction and maintenance of general anesthesia, as well as the sedation of critically ill patients during mechanical ventilation or patients undergoing surgical or diagnostic procedures. Although, propofol has been established as a safe and effective drug for the sedation of patients in the intensive care unit (ICU) (1), its applicability is restricted when long-term administration is required. Tolerance may develop if administration exceeds 5 days in adults (2) or 2 days in children (3) . The subsequent long-term administration of propofol at large doses is a triggering factor for the development of propofol infusion syndrome (4) . Rare in adults, but common in children, this syndrome is usually fatal and is a major consideration for the long-term use of propofol in the ICU.
We believe that the creation of an animal model in which tolerance develops to propofol's sedative effect would facilitate research on the pathogenesis of the phenomenon as well as on strategies for its prevention or amelioration. Such a model is presented here in rabbits undergoing prolonged mechanical ventilation.
METHODS
Six healthy male New Zealand White rabbits, 6 mo old, weighing 4.0 to 4.5 kg, were used. They were housed individually in wire cages under controlled environmental conditions (20 -22°C room temperature, 50%-60% relative humidity, 12-h light/12-h dark cycle). The facilities were in compliance with Directive 86/609/EEC. The animals were provided with 125 g of commercial pelleted diet (certified rabbit chow #51, EL.VI.Z., Xanthi, Greece) per day and tap water ad libitum.
All animals were endotracheally intubated under xylazine-ketamine anesthesia and their lungs were mechanically ventilated. At the first signs of awakening, continuous IV infusion of propofol was started to keep the animals under sedation for 48 h. The infusion rate (IR) was adjusted, if needed, to maintain the desired level of sedation (Table 1) and was recorded every 60 min. Propofol concentration was measured in arterial plasma 30 min after every other IR adjustment, provided there was adequate level of sedation, using high-performance liquid chromatography (HPLC) to define the type of tolerance and calculate the systemic clearance rates during the experiment. The clearance rate was calculated using the equation CL ϭ IR ⅐ C
Ϫ1
where CL is clearance rate, IR is propofol infusion rate expressed as mg ⅐ h Ϫ1 and C is arterial plasma concentration of propofol expressed as mg ⅐ L Ϫ1 . The experimental protocol was approved by the Ethics Committee of the local Veterinary Service, as it was in compliance with Directive 86/609/EEC.
The course of the experiment was described based on the patterns of a) propofol IR adjustments (expressed as percentage of initial-IR increase to initial IR, estimated on an hourly basis), b) arterial plasma propofol concentration changes in relation to IR (measured 30 min after every other IR adjustment, provided there was an adequate level of sedation) and c) systemic clearance rates (calculated at the same time points as (b)). Two types of tolerance were distinguished: the pharmacokinetic type, which was characterized by a need for an IR increase to maintain the desired sedation level accompanied by constant or decreasing blood propofol concentrations, and the pharmacodynamic type, which was characterized by a need for an IR increase to maintain the desired sedation level accompanied by an increase of propofol concentrations.
After overnight fasting, the animals were premedicated with atropine (0.05 mg/kg, IM) and xylazine (5 mg/kg, IM) and, 20 min later, were anesthetized with ketamine hydrochloride (50 mg/kg, IM). They were then endotracheally intubated and connected to a pressure ventilator (ADS 1000 Veterinary Anesthesia Delivery System; Engler, FL A 6-lead electrocardiogram (ECG), invasive arterial blood pressure, heart rate, and Spo 2 (Dash 3000 patient monitor; Marquette, Milwaukee, WI), as well as respiratory rate and body temperature (SDI Vet Ox 4700 Plus monitor; SDI, Kansas City, MO) were continuously measured, and arterial blood gases and the acid-base status and the levels of electrolytes and glucose were assessed every 2 h (GEM Premier 3000/IL; Lexington, MA). NaHCO 3 solution was administered IV if metabolic acidosis occurred. Electrolytes and glucose levels were corrected if necessary. Electrocardiogram electrodes were attached on the lateral aspects of shoulders and thighs. A central ear artery and two marginal ear veins were catheterized (23-gauge polyethylene catheter) to provide intraarterial and IV access, respectively. Spo 2 and body temperature were measured using rectal electrodes. The animals were placed at lateral recumbency on a heated-surface (36°C) operation table and were covered with an isothermic blanket to keep them normothermic; their position was changed (left lateral-right lateral) every 6 h. The urinary bladder was catheterized using a 10 CH Foley catheter to facilitate urine collection. During the experiment, the animals received either lactated Ringer's solution or dextrose 5% saline IV for electrolyte and fluid support. The basic rule that guided fluid administration management was "urine volume ϩ blood sample volume ϭ total drug volume ϩ saline volume ϩ hydroxyethyl starch volume." Hydroxyethyl starch (Voluven, Freefex) replaced blood sample volume, and saline replaced all other losses. Each animal also received 300 IU tinzaparin sodium (Innohep, Leo) subcutaneously every 12 h for thrombosis prophylaxis.
Propofol was administered in the form of 2% oilin-water injectable emulsion (Diprivan 2% inj, Zeneca Spa, Italy). At the first signs of awakening from general anesthesia (restoration of corneal reflex), the animals received propofol by continuous IV infusion using an infusion pump (Module DPS Orchestra I.S.; Fresenious Vial S.A., Brezins, France) at an initial IR of 20 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 . The IR was adjusted, when necessary, in steps of 5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 to maintain the desired level of sedation. The level of sedation was assessed based on reflex responses every 30 min; earlier assessments were made only if clinical signs indicating awakening (25% increase of heart rate and/or arterial blood pressure from previous measurement, any increase of respiratory rate from ventilator setting) were present. The criteria for the desired level of sedation are listed in Table 1 . To avoid propofol overdose, if the IR had to be reduced to maintain an adequate level of sedation, attempts were made to decrease the IR (in steps of 5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 ) every 15 min until the appearance of initial signs of awakening (increased heart rate, increased arterial blood pressure, restoration of palpebral reflex, restoration of pina and pedal reflexes at light painful stimuli); in these cases the IR was increased again back to the previous safe point. Arterial blood samples were collected in test tubes containing EDTA and centrifuged at 3000 rpm for 15 min to obtain plasma, which was stored at Ϫ40°C until propofol analysis. An isocratic HPLC system consisting of a Jasco Pump BIP-1 (Jasco, Tokyo, Japan), and a Shimadzu RF -535 fluorescence detector (Shimadzu, Kyoto, Japan) were used for propofol analysis. The response signal of the detector was acquired digitally and the data were saved in ASCII format for further manipulation (peak height/area measurement, digital filtering) using homemade software (Laboratory of Physical Chemistry, Department of Chemistry, Aristotle University, Thessaloniki, Greece). HPLC separations were performed on a 250 ϫ 4.6 mm C18 Kromasil 4 m analytical column from MZ-Analysentechnik (Mainz, Germany) protected by a guard column (20 ϫ 2 mm filled with C18 bonded silica). The mobile phase consisted of 38% v/v aqueous solution Na 2 HPO 4 /NaH 2 PO 4 20 mM each with pH ϭ 3.4 adjusted with concentrated H 3 PO 4 and 62% v/v acetonitrile. The flow rate was set at 1.3 mL/min and the injected volume was 25 L (injector Rheodyne 7125; Cotati, CA). The Shimadzu RF-535 spectrofluorometric detector operated at ex ϭ 276 nm and em ϭ 310 nm.
After thawing, 200 L plasma from each sample was diluted with 100 L of acetonitrile and 100 L trichloroacetic acid. The resulting solution was vortexmixed for 2 min and centrifuged for 15 min at 13000 rpm to separate the precipitated proteins. Twenty-five L of the supernatant was injected into the HPLC column. For quantitation purposes, calibration curves were constructed with the addition (spiking) of propofol in plasma. Appropriate amounts of propofol and thymol (used as internal standard) solutions were added to rabbit plasma to provide 10 different propofol concentrations ranging from 0.078 to 40 g/mL. Thymol concentration was kept constant at 50 g/mL.
Each sample was analyzed four times, and the average peak area ratio values (propofol to internal standard thymol) were used for linear regression analysis. Very good sensitivity was achieved in the fluorescence detector reaching low limits of detection (11 g/L). The overall linearity and the reproducibility of the method were found to be very satisfactory (linear regression R 2 ϭ 0.9997, RSD ϭ 4.5% for the analysis of plasma spiked at 1 g/mL, n ϭ 6).
Autopsy was performed in those animals that did not survive their intended survival period. A postmortem histopathological examination was performed to the liver, the principal organ of metabolism, to highlight the pathogenetic mechanism of the phenomena studied. For this reason, the liver was excised at autopsy and immediately fixed in 10% neutral buffered formaldehyde. Tissue samples, fixed in formaldehyde, were dehydrated, embedded in paraffin wax, serially sectioned at 3 m and stained routinely with hematoxylin-eosin. Slides were subjected to histological examination under an Olympus BX40 microscope.
Data of propofol plasma concentrations and clearance rates during the phases of the experiment were expressed as means Ϯ sd and subjected to analysis of variance for repeated measures. The significance of the means was tested by the Student's t-test. A probability of P Ͻ 0.05 was considered statistically significant.
RESULTS
The mortality rate was 100% and the animals survived for 23-36 h (mean Ϯ sd: 30.8 Ϯ 6.0 h). The first findings of deterioration were metabolic acidosis and decreased Spo 2 and Po 2 followed by findings of low cardiac output (decreased diuresis, low arterial blood pressure). The vital signs during the experiment are presented in Table 2 . The clinical course during the last hours of the experiment, as well as the autopsy findings, suggested pulmonary edema as the most probable cause of death. Major clinical and laboratory findings included Spo 2 Ͻ90%, Po 2 Ͻ90 mm Hg (at 100% Fio 2 ), coarse rales on auscultation and finally frothy edema fluid emanating from the endotracheal tube.
Major macroscopic findings of the lungs at autopsy included lung enlargement and congestion and pink frothy edema fluid effusing from lung sections and filling the tracheal cannula. Lungs and liver had milky tincture. Histopathological examination of the liver revealed low-grade active hepatitis with lymphocytic inflammation, which was scattered through lobule in all the animals.
Hourly propofol initial-IR adjustments (expressed as percentage of initial-IR increase at a given time point to initial-IR) during the experiment are shown in Figure 1 . The course of IR adjustments followed a 5-phase pattern: 1) phase 1 (mean duration Ϯ sd 1.2 Ϯ 0.6 h); steady IR, 2) phase 2 (9.4 Ϯ 5.5 h); increasing IRs, 3) phase 3 (2.3 Ϯ 1.2 h); steady high-IR, 4) phase 4 (13.7 Ϯ 1.9 h); decreasing IRs and 5) phase 5 (5.0 Ϯ 2.7 h); steady low-IR. The mean maximum IR was 219.7% Ϯ 35.7% of the initial IR.
Propofol measurements did not include the last 3-4 h when the animals were nearly moribund (clinical signs of severe pulmonary edema, significant deterioration of blood gases, and severe acidosis). Arterial propofol concentrations and propofol IRs in relation to the time course of the experiment are shown in Figure  2 . In all the animals, the course of propofol concentrations during the experiment in relation to propofol IR followed a 3-phase pattern: 1) phase I (mean duration Ϯ sd 6.0 Ϯ 2.7 h); propofol concentration, after an initial increase, remained steady while IRs were increasing, 2) phase II (5.8 Ϯ 2.5 h); propofol concentrations were increasing while IRs were increasing and 3) phase III (18.8 Ϯ 3.3 h); propofol concentrations were increasing while IRs were decreasing. Mean propofol concentrations at each phase are presented in Table 3 . The propofol concentration at "steady state" was significantly larger (P Ͻ 0.001) than that measured 30 min after the onset of infusion (baseline). The propofol level during the "increasing concentration" phase was significantly higher (P Ͻ 0.001) than that at steady state.
Propofol's systemic clearance rates for each animal are shown in Figure 3 . In all animals, the propofol clearance rate, after an initial high value, was progressively increased for 6.0 Ϯ 2.7 h and then decreased for 24.6 Ϯ 4.7 hours. Mean propofol clearance rates for each phase are presented in Table 4 . Clearance during the "increase rate" phase was significantly less (P Ͻ 0.05) than that measured 30 min after the onset of infusion (baseline). Clearance during the "decreasing rate" phase was also significantly less (P Ͻ 0.01) than that at the increasing rate phase.
DISCUSSION
Tolerance of propofol's sedative effect has been reported in clinical studies (2, 3, 5, 6) . To the authors' knowledge, this is the first animal model in which tolerance develops to propofol's sedative effect in healthy rabbits during prolonged mechanical ventilation. Tolerance was accompanied by changes in Values are mean Ϯ SD; n ϭ 6. *P Ͻ 0.05 compared with baseline; †P Ͻ 0.01 compared with "increasing rate."
propofol's systemic clearance rate, which was progressively increased and then gradually decreased, leading to significant accumulation of the drug. Tolerance to propofol's sedative effect may develop during long-term administration in critically ill adult (2) or pediatric patients during mechanical ventilation (3). In a 3-week ICU dog model, the administration of propofol in combination with pentobarbital did not result in the development of propofol tolerance (7) . On the contrary, in our rabbit model, propofol IRs had to be increased within the first 1-2 hours after the onset of the infusion to maintain the same sedation level. After a short period of steady-IR, dose requirements were dramatically increased to approximately 220% of the initial dose. Then, a steady high-IR period was followed by a progressively decreasing IR phase and finally a steady low-IR phase until the death of the animals.
⌱n our study, mortality was 100% for the 48-hour study period and was related to propofol sedation. There is evidence that rabbits can survive mechanical ventilation for 49 Ϯ 1 hours (8) or even 51 Ϯ 3 hours (9) under continuous IV infusion of sodium thiopental. It has also been shown that rabbits can be maintained under halothane anesthesia for at least 36 hours with their vital signs remaining within normal limits throughout the anesthetic period (10) . In agreement with our findings, Gronert et al. (7) also reported frequent mortality (54.5%) in mechanically ventilated dogs sedated with propofol plus pentobarbital. However, there are no data on the exact day of deaths (2 nd -18 th day) and whether these were attributable to propofol administration or other pathological conditions.
Tolerance is defined as a reduction in response to a drug after repeated administration and therefore the need for a increase in the dose to obtain the same drug effect. Among a number of types of tolerance that represent different pathogenic mechanisms, the pharmacokinetic and pharmacodynamic are the most commonly distinguished. The pharmacokinetic type refers to changes in the distribution or metabolism of the drug after repeated administration that lead to a reduction in blood concentrations and subsequently at the site of drug action. The pharmacodynamic type refers to adaptive changes that have taken place within systems affected by the drug so that response to a given concentration of the drug is reduced. This involves changes in receptor density or efficiency of receptor coupling to signal transduction pathways (11) . To differentiate between the two types of tolerance, blood or plasma propofol concentrations have to be determined. In a clinical study, among six ICU patients who required increasing propofol doses to maintain the desired level of sedation, three developed tolerance associated with increased blood propofol levels, whereas the others had reduced or unchanged levels indicative of increased rate of propofol clearance (2) . In our study, plasma propofol concentrations were not correlated with the trend of infusion rate adjustments. The initial increase of propofol concentration at approximately 1-2 hours after starting the infusion was probably attributable to the time needed for propofol to reach a steady state plasma concentration. Systemic clearance was high 30 min after the onset of infusion, probably as a result of increased distributional clearance. Thereafter, despite the continuously increasing IR, propofol concentrations remained stable, whereas the clearance rate was progressively increased. Animal studies have shown an inverse relation between blood propofol concentrations and cardiac output under constant propofol infusion (12, 13) . Higher cardiac outputs imply more rapid blood flow to the organs of propofol elimination and distribution, which increases the rate of their clearance and distribution resulting in smaller recirculated concentrations.
Another plausible mechanism that could explain the development of pharmacokinetic tolerance could be the increased distribution of the drug in adipose tissue. Because of its highly lipophilic properties, propofol may be accumulated in body fat (14) , which acts as an important reservoir for lipid-soluble drugs. However, fat fills slowly and probably clears nearly all of the propofol that flows through it. If the blood flow to the fat increases over the course of the experiment it would also increase the distributional clearance of propofol to the fat until steady-state was reached, but that probably does not occur for days. With this perspective, the measurement of urinary metabolites would permit defining the degree of participation of these two plausible mechanisms (increased systemic propofol clearance and increased propofol distribution into fat) to the development of pharmacokinetic tolerance.
At a latter phase, increasing IRs were accompanied by progressively increasing plasma propofol concentrations, which suggested the development of pharmacodynamic tolerance because the level of sedation remained stable. Furthermore, after a steady high-IR phase, dose requirements were progressively reduced, whereas propofol levels were dramatically increased. With continuous infusion, a highly lipophilic drug may accumulate extensively in fat, which becomes a reservoir for the maintenance of the plasma concentration and therefore the brain concentration at, or even above, the threshold required for the therapeutic effect (15) . Studies on the kinetics of propofol when given for sedation in ICU patients show increased recovery times when deep levels of sedation are maintained and infusions are prolonged as a result of significant accumulation of the drug and saturation of peripheral tissues and short recovery times at light levels of sedation and short infusion periods (16) . In the present study, there was significant accumulation of propofol, which was shown by the dramatic increase of the drug's plasma levels and was accompanied by decreasing clearance rates. Based on the histopathological findings, we can assume that the toxic effect of propofol on the liver could be related to the gradual decrease noted in propofol's metabolic clearance. Although one would expect an increase in the depth of sedation, this remained unchanged, as evidence of persisting and developing pharmacodynamic tolerance. This increase to the magnitude of tolerance may have been a result of changes in the number and/or the responsiveness of the drug's receptors.
In conclusion, according to our results, all the mechanically ventilated rabbits receiving propofol developed pharmacokinetic tolerance to propofol's sedative effect within the first 1-2 hours, accompanied by increasing systemic clearance rates. As a result, propofol had to be infused at larger doses to maintain the same level of sedation. Subsequently, propofol clearance rates were gradually decreased, leading to accumulation, probably as a result of a breakdown of the liver's metabolic efficiency, while pharmacodynamic tolerance also occurred. The mechanisms of propofol tolerance have not been fully elucidated. We believe that the present animal model could be used for the study of the pathogenesis, as well as the prevention and amelioration of the phenomenon.
